Read full article 19 November 2020, 5:53 am·5-min read Pfizer Inc and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday. The vaccine's efficacy was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people. The U.S. Food and Drug Administration could grant emergency-use by the middle of December, BioNTech Chief Executive Ugur Sahin told Reuters TV. Conditional approval in the European Union...
Full ArticlePfizer-BioNTech Vaccine Deliveries Could Start 'Before Christmas'
WorldNews
0 shares
1 views
You might like
Related news coverage
Coronavirus vaccine rollout to hospitals 'in 10 days' time'
Hull Daily Mail
Hospitals in England could expect to receive their first deliveries of a vaccine produced by Pfizer/BioNTech as soon as Monday..
Advertisement
More coverage
Trump says coronavirus vaccine deliveries will start next week
Upworthy
The comments come ahead of a Dec. 10 meeting where FDA regulators will review Pfizer and BioNTech's request for an emergency use...
-
FTSE 100 enjoys delayed vaccine boost; AO World succumbs to profit-taking after stellar run
Proactive Investors
-
Pfizer, Moderna COVID-19 vaccine candidates may get EU approval in December
Proactive Investors
-
Pfizer-BioNTech COVID-19 vaccine deliveries could start 'before Christmas': BioNTech CEO
SeekingAlpha
-
COVID-19: Pfizer-BioNTech vaccine deliveries could start by this month, if 'all goes well'
Zee News